Wanbangde Pharmaceutical Holding Group Co., Ltd. (002082.SZ)
CNY 7.0
(-2.51%)
CNY 7.0
(-2.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -72.86 Million | -239.64 Million | 22.08 Million | 151 Million | -248.69 Million | 135.39 Million |
| Net Income | 26.32 Million | 74.32 Million | 161.15 Million | 292.21 Million | 208.83 Million | 125.18 Million |
| Depreciation & Amortization | 96.93 Million | 107.03 Million | 94.97 Million | 107.11 Million | 68.25 Million | 69.37 Million |
| Deferred income taxes | -21.6 Million | -31.18 Million | -15.26 Million | -23.47 Million | 1.34 Million | -4.04 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -278.24 Million | -590.19 Million | -162.87 Million | -406.15 Million | -587.58 Million | -86.93 Million |
| Other non-cash items | 48.19 Million | 169.18 Million | -71.17 Million | 157.83 Million | 61.8 Million | 27.77 Million |
| Investing Cash Flow | -156.03 Million | -167.41 Million | 999.45 Million | -680.64 Million | -394.51 Million | -426.87 Million |
| Investments in PPE | -128.72 Million | -167.23 Million | -277.05 Million | -559.24 Million | -405.97 Million | -199.63 Million |
| Acquisitions | 200.6 Thousand | 6.37 Million | 1.29 Billion | -79.9 Million | -27.94 Million | -224.18 Million |
| Investment purchases | -5 Million | -6.37 Million | 266.61 Thousand | -44.8 Million | -22.23 Million | - |
| Sales/Maturities of investments | 7.49 Million | 500 Thousand | 1.19 Million | 5.51 Million | 500 Thousand | 500 Thousand |
| Other Investing Activities | -30 Million | -686.16 Thousand | -17.67 Million | -2.21 Million | 61.14 Million | -3.54 Million |
| Financing Cash Flow | 9.25 Million | -63.06 Million | -674.74 Million | 439.61 Million | 765.34 Million | 417.79 Million |
| Debt repayment | -112.98 Million | -710.72 Million | -1.01 Billion | -1.26 Billion | -276.08 Million | -50 Million |
| Dividends payments | -73.4 Million | -43.9 Million | -122.85 Million | -92.73 Million | -50.21 Million | -24.72 Million |
| Common Stock Repurchased | - | -9.02 Million | -50.96 Million | - | - | - |
| Common Stock Issuance | - | 9.02 Million | 50.96 Million | - | - | - |
| Other Financing Activities | 18.3 Million | 691.56 Million | 529.84 Million | 1.87 Billion | 1.09 Billion | 492.52 Million |
| Accounts receivables | -15.19 Million | -101.79 Million | 178.82 Million | -626.93 Million | -501.34 Million | -171.69 Million |
| Accounts payables | -262.25 Million | -438.5 Million | -390.96 Million | 309.04 Million | -48.68 Million | 173.82 Million |
| Inventory | 20.81 Million | -18.7 Million | 64.52 Million | -64.78 Million | -167.24 Million | -85.02 Million |
| Other working capital | -283.85 Million | -31.18 Million | -15.26 Million | -23.47 Million | 129.67 Million | -1.91 Million |
| Cash at beginning of period | 439.04 Million | 907.15 Million | 565.8 Million | 652.89 Million | 399.34 Million | 273.08 Million |
| Cash at end of period | 218.15 Million | 439.04 Million | 907.15 Million | 565.8 Million | 522.04 Million | 399.34 Million |
| Capital Expenditure | -128.72 Million | -167.23 Million | -277.05 Million | -559.24 Million | -405.97 Million | -199.63 Million |
| Effect of forex changes on cash | -1.24 Million | 2.02 Million | -5.44 Million | 2.93 Million | 562.16 Thousand | -62.23 Thousand |
| Net cash flow / Change in cash | -220.89 Million | -468.1 Million | 341.35 Million | -87.08 Million | 122.7 Million | 126.25 Million |
| Free Cash Flow | -201.59 Million | -406.87 Million | -254.97 Million | -408.23 Million | -654.67 Million | -64.24 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 8 Million | 8.86 Million | 28.83 Million | 26.32 Million | 56.17 Million | -38.55 Million |
| Depreciation & Amortization | - | 26.08 Million | 26.08 Million | 96.93 Million | 96.93 Million | 19.2 Million |
| Deferred income taxes | - | - | - | -21.6 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -204.03 Million | - | -278.24 Million | 5.61 Million | - |
| Other non-cash items | 18.17 Million | 37.5 Million | 72.51 Million | 48.19 Million | -86.98 Million | 42.39 Million |
| Investing Cash Flow | -44.92 Million | 15.89 Million | -164.2 Million | -156.03 Million | -6.32 Million | -82.19 Million |
| Investments in PPE | -97.08 Million | 20.8 Million | -66.17 Million | -128.72 Million | 37.75 Million | -81.04 Million |
| Acquisitions | 47.67 Million | 384.97 Thousand | 254.44 Thousand | 200.6 Thousand | -2.26 Million | 3669.79 |
| Investment purchases | -1.75 Million | - | - | -5 Million | -5 Million | - |
| Sales/Maturities of investments | 6.19 Million | 5.39 Million | 340.73 Thousand | 7.49 Million | -7.29 Million | -415.2 Thousand |
| Other Investing Activities | 47.71 Million | -10.69 Million | -98.62 Million | -30 Million | -29.52 Million | -731.6 Thousand |
| Financing Cash Flow | -36.46 Million | -78.68 Million | 27.98 Million | 9.25 Million | -153.74 Million | 93.6 Million |
| Debt repayment | -12.28 Million | -70.23 Million | -41.2 Million | -112.98 Million | -127.05 Million | -224.39 Million |
| Dividends payments | -61.3 Million | -6.67 Million | -13.2 Million | -73.4 Million | -73.4 Million | -12.46 Million |
| Common Stock Repurchased | - | - | - | - | -454.19 Thousand | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 12.55 Million | -1.77 Million | -20.95 Thousand | 18.3 Million | -9.01 Million | 330.46 Million |
| Accounts receivables | - | -202.25 Million | - | -15.19 Million | -15.19 Million | - |
| Accounts payables | - | - | - | -262.25 Million | - | - |
| Inventory | - | -11.35 Million | - | 20.81 Million | 20.81 Million | - |
| Other working capital | - | 9.57 Million | - | - | - | - |
| Cash at beginning of period | 135.42 Million | 183.65 Million | 218.15 Million | 439.04 Million | 307.04 Million | 291.81 Million |
| Cash at end of period | 73.76 Million | 135.42 Million | 183.65 Million | 218.15 Million | 218.15 Million | 307.04 Million |
| Capital Expenditure | -97.08 Million | 20.8 Million | -66.17 Million | -128.72 Million | 37.75 Million | -81.04 Million |
| Effect of forex changes on cash | -245.77 Thousand | -325.24 Thousand | 369.9 Thousand | -1.24 Million | -557.01 Thousand | -17.08 Thousand |
| Net cash flow / Change in cash | -61.66 Million | -48.22 Million | -34.49 Million | -220.89 Million | -88.89 Million | 15.23 Million |
| Free Cash Flow | -70.91 Million | 41.09 Million | 35.18 Million | -201.59 Million | 109.49 Million | -77.2 Million |
STARHEALTH
THRU
OGC
AST
3454
ROAOF